Jong-Hoon Kim1, Vittal Mogasale2, Colleen Burgess3, Thomas F Wierzba4. 1. International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, South Korea. Electronic address: jonghoon.kim@ivi.int. 2. International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, South Korea. Electronic address: vmogasale@ivi.int. 3. MathEcology, LLC, 3120 West Carefree Hwy, Suite 1-642, Phoenix, AZ 85086, USA. Electronic address: Colleen.Burgess@mathecology.com. 4. PATH, 455 Massachusetts Avenue NW, Suite 1000, Washington, DC 20001, USA. Electronic address: twierzba@path.org.
Abstract
BACKGROUND: Impact evaluation of vaccination programs is necessary for making decisions to introduce oral cholera vaccines (OCVs) in cholera-endemic countries. METHODS: We analyzed data to forecast the future global burden of cholera. We developed a mathematical model of cholera transmission in three countries as examples: Nigeria, Uganda, and Indonesia. After fitting the model, we evaluated the impact of OCVs delivered in four vaccination strategies varying by target age group and frequency of vaccination over the period of 2015-2030. RESULTS: Data suggest that the global annual incidence of cholera will increase from 3046238 in 2015 to 3787385 in 2030 with the highest burden in Asia and Africa where overall population size is large and the proportion of population with access to improved sanitation facilities is low. We estimate that OCV will reduce the cumulative incidence of cholera by half in Indonesia and >80% in Nigeria and Uganda when delivered to 1+ year olds every three years at a coverage rate of 50%, although cholera may persist through higher coverage rates (i.e., >90%). The proportion of person-to-person transmission compared to water-to-person transmission is positively correlated with higher vaccination impact in all three countries. CONCLUSIONS: Periodic OCV vaccination every three or five years can significantly reduce the global burden of cholera although cholera may persist even with high OCV coverage. Vaccination impact will likely vary depending on local epidemiological conditions including age distribution of cases and relative contribution of different transmission routes.
BACKGROUND: Impact evaluation of vaccination programs is necessary for making decisions to introduce oral cholera vaccines (OCVs) in cholera-endemic countries. METHODS: We analyzed data to forecast the future global burden of cholera. We developed a mathematical model of cholera transmission in three countries as examples: Nigeria, Uganda, and Indonesia. After fitting the model, we evaluated the impact of OCVs delivered in four vaccination strategies varying by target age group and frequency of vaccination over the period of 2015-2030. RESULTS: Data suggest that the global annual incidence of cholera will increase from 3046238 in 2015 to 3787385 in 2030 with the highest burden in Asia and Africa where overall population size is large and the proportion of population with access to improved sanitation facilities is low. We estimate that OCV will reduce the cumulative incidence of cholera by half in Indonesia and >80% in Nigeria and Uganda when delivered to 1+ year olds every three years at a coverage rate of 50%, although cholera may persist through higher coverage rates (i.e., >90%). The proportion of person-to-person transmission compared to water-to-person transmission is positively correlated with higher vaccination impact in all three countries. CONCLUSIONS: Periodic OCV vaccination every three or five years can significantly reduce the global burden of cholera although cholera may persist even with high OCV coverage. Vaccination impact will likely vary depending on local epidemiological conditions including age distribution of cases and relative contribution of different transmission routes.
Authors: Matthew D Phelps; Andrew S Azman; Joseph A Lewnard; Marina Antillón; Lone Simonsen; Viggo Andreasen; Peter K M Jensen; Virginia E Pitzer Journal: PLoS Negl Trop Dis Date: 2017-11-27
Authors: Laurent Akilimali Mukelenge; Jean-Claude B Anné; Abiba Banla Kere; Lucienne Dempouo; Sakoba Keita; José P M Langa; Issa Makumbi; Elibariki R Mwakapeje; Ian J Njeru; Olubunmi E Ojo; Isaac Phiri; Aline Munier; Berthe-Marie Njanpop-Lafourcade; Delphine Sauvageot; Raymond B Mhlanga; Léonard Heyerdahl; Johara Nadri; Richard Wood; Issaka Ouedraogo; Alexandre Blake; Lorenzo Pezzoli; Bradford D Gessner; Martin Mengel Journal: BMC Proc Date: 2017-01-31
Authors: Elizabeth C Lee; Andrew S Azman; Joshua Kaminsky; Sean M Moore; Heather S McKay; Justin Lessler Journal: PLoS Med Date: 2019-12-11 Impact factor: 11.069